• General information
  • Organism: 5 Plasmodium species (P. falciparum, P. vivax, P. ovale, P. malariae, P. knowlesi)
    • P. falciparum is responsible for most severe disease.
    • P. vivax and P. ovale are responsible for recrudescent disease.
  • Transmission via the female Anopheles mosquito, which bites at night or in the early morning.
  • Endemic in Asia, Africa, Central America, and South America

• Clinical presentation
  • Initially, the patient presents with an acute febrile illness: fever, chills, headache, nausea, lethargy, and upper respiratory symptoms.
  • Infection with P. falciparum can further progress to severe organ dysfunction.
  • The disease course is unpredictable in the non-immune individual.

• Diagnosis
  • Thick and thin peripheral blood smears demonstrating organism
    • Thick smear – confirms Plasmodium parasites
    • Thin smear – allows speciation of Plasmodium parasites
  • Hyperparasitemia is associated with increased mortality

• Treatment
  • P. falciparum or species unidentified
    • For severe malaria, IV quinine (quinidine if quinine not available)
    • IV artusenate is available from the CDC as a quinidine/quinine alternative.
    • DO NOT USE Chloroquine for severe malaria
  • Patients with evidence of complicated malaria (>3% parasitemia, signs of organ dysfunction, alterations in mental status) should be admitted to an ICU.

 

University of Maryland Section for Global Emergency Health

Author: Emilie J.B. Calvello, MD, MPH

References

Center for Disease Control. (2012). Malaria.  Retrieved November 9, 2012, from http://www.cdc.gov/MALARIA/

Wattal, C. et al. Infectious disease emergencies in returning travelers: special referece to malaria, dengue and chikungunya. Med Clin North Am. 2012 Nov; 96(6): 1225 – 55.